Biovail Vasotec/Cardizem Fixed-Dose Combination Data Expected By July
Executive Summary
Biovail expects results from a Phase III trial of several fixed-dose combinations of Vasotec and Cardizem XL in the first half of the year
You may also be interested in...
Biovail Cardizem XL “approvable”
Biovail receives "approvable" letter for Cardizem XL, company announces June 17. Approval of the diltiazem extended-release formulation is "subject to the completion of labeling matters and the submission and review of requested information," Biovail says. Biovail is adding 500 reps to its 300-rep sales force in preparation for the launch of Cardizem XL (1"The Pink Sheet" May 20, p. 21)...
Biovail Cardizem XL “approvable”
Biovail receives "approvable" letter for Cardizem XL, company announces June 17. Approval of the diltiazem extended-release formulation is "subject to the completion of labeling matters and the submission and review of requested information," Biovail says. Biovail is adding 500 reps to its 300-rep sales force in preparation for the launch of Cardizem XL (1"The Pink Sheet" May 20, p. 21)...
Biovail Cardizem XL NDA Highlights Nighttime Dose For Cardiac AE Prevention
Biovail's NDA for hypertension agent Cardizem XL (diltiazem) highlights nighttime dosing aimed at achieving maximum drug levels between 6 a.m. and noon, when the majority of adverse cardiac events take place.